vs

Side-by-side financial comparison of Q32 Bio Inc. (QTTB) and REZOLVE AI PLC (RZLV). Click either name above to swap in a different company.

Q32 Bio Inc. is the larger business by last-quarter revenue ($1.9M vs $1.2M, roughly 1.6× REZOLVE AI PLC). Q32 Bio Inc. runs the higher net margin — 2991.2% vs -1078.8%, a 4070.0% gap on every dollar of revenue.

Q32 Bio Inc. is a clinical-stage biotechnology company focused on developing targeted antibody-based immunotherapies for autoimmune disorders, inflammatory conditions and rare immunological diseases with unmet medical needs, operating primarily across North America and European markets.

REZOLVE AI PLC is a UK-based technology firm developing AI-powered mobile engagement and instant transaction platforms. Its solutions let consumers complete purchases directly from audio, video, and print content, serving retail, consumer goods, and media clients across Europe, North America, and select APAC markets.

QTTB vs RZLV — Head-to-Head

Bigger by revenue
QTTB
QTTB
1.6× larger
QTTB
$1.9M
$1.2M
RZLV
Higher net margin
QTTB
QTTB
4070.0% more per $
QTTB
2991.2%
-1078.8%
RZLV

Income Statement — Q4 FY2025 vs Q2 FY2025

Metric
QTTB
QTTB
RZLV
RZLV
Revenue
$1.9M
$1.2M
Net Profit
$57.7M
$-13.0M
Gross Margin
Operating Margin
-808.4%
Net Margin
2991.2%
-1078.8%
Revenue YoY
Net Profit YoY
506.9%
EPS (diluted)
$4.70

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
QTTB
QTTB
RZLV
RZLV
Q4 25
$1.9M
Q3 25
$-220.0K
Q2 25
$-284.0K
$1.2M
Q1 25
$-371.0K
Q4 24
$0
Q3 24
$0
Q2 24
$0
Q1 24
$0
Net Profit
QTTB
QTTB
RZLV
RZLV
Q4 25
$57.7M
Q3 25
$-7.4M
Q2 25
$-9.5M
$-13.0M
Q1 25
$-11.0M
Q4 24
$-14.2M
Q3 24
$-17.6M
Q2 24
$-17.0M
Q1 24
$1.0M
Operating Margin
QTTB
QTTB
RZLV
RZLV
Q4 25
Q3 25
3444.1%
Q2 25
3229.2%
-808.4%
Q1 25
3296.0%
Q4 24
Q3 24
Q2 24
Q1 24
Net Margin
QTTB
QTTB
RZLV
RZLV
Q4 25
2991.2%
Q3 25
3358.6%
Q2 25
3341.2%
-1078.8%
Q1 25
2973.3%
Q4 24
Q3 24
Q2 24
Q1 24
EPS (diluted)
QTTB
QTTB
RZLV
RZLV
Q4 25
$4.70
Q3 25
$-0.60
Q2 25
$-0.78
Q1 25
$-0.90
Q4 24
$2.63
Q3 24
$-1.46
Q2 24
$-1.42
Q1 24
$-6.33

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
QTTB
QTTB
RZLV
RZLV
Cash + ST InvestmentsLiquidity on hand
$48.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$42.0M
$-14.3M
Total Assets
$61.8M
$80.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
QTTB
QTTB
RZLV
RZLV
Q4 25
$48.3M
Q3 25
$49.0M
Q2 25
$54.8M
Q1 25
$65.5M
Q4 24
$78.0M
Q3 24
$89.1M
Q2 24
$97.7M
Q1 24
$115.5M
Stockholders' Equity
QTTB
QTTB
RZLV
RZLV
Q4 25
$42.0M
Q3 25
$-18.4M
Q2 25
$-12.2M
$-14.3M
Q1 25
$-4.0M
Q4 24
$5.7M
Q3 24
$18.3M
Q2 24
$33.5M
Q1 24
$48.8M
Total Assets
QTTB
QTTB
RZLV
RZLV
Q4 25
$61.8M
Q3 25
$57.8M
Q2 25
$66.1M
$80.1M
Q1 25
$79.1M
Q4 24
$92.3M
Q3 24
$104.5M
Q2 24
$124.2M
Q1 24
$152.3M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
QTTB
QTTB
RZLV
RZLV
Operating Cash FlowLast quarter
$-6.2M
$-4.9M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
-0.11×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
QTTB
QTTB
RZLV
RZLV
Q4 25
$-6.2M
Q3 25
$-4.2M
Q2 25
$-10.7M
$-4.9M
Q1 25
$-12.5M
Q4 24
$-11.4M
Q3 24
$-19.5M
Q2 24
$-22.2M
Q1 24
$-14.6M
Free Cash Flow
QTTB
QTTB
RZLV
RZLV
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$-11.4M
Q3 24
$-19.6M
Q2 24
$-22.2M
Q1 24
Capex Intensity
QTTB
QTTB
RZLV
RZLV
Q4 25
Q3 25
0.0%
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Cash Conversion
QTTB
QTTB
RZLV
RZLV
Q4 25
-0.11×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
-14.14×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons